Edesa Biotech, Inc. — Director's Dealing 2023

Jan 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edesa Biotech, Inc. (EDSA)
CIK: 0001540159
Period of Report: 2023-01-09

Reporting Person: van der Velden Peter (10% Owner)
Reporting Person: Lumira Capital Investment Management Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-09	Common share	S	132845	$2.6621	Disposed	1764583	Indirect
2023-01-09	Common share	S	12284	$2.6621	Disposed	163170	Indirect
2023-01-10	Common share	S	139450	$2.6346	Disposed	1625133	Indirect
2023-01-10	Common share	S	12895	$2.6346	Disposed	150275	Indirect

Footnotes

F1: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.